Venture firms exit PowderMed in Pfizer deal
Global pharmaceuticals group Pfizer paid a reported $400m to acquire PowderMed, a UK DNA-vaccines company backed by Advent Venture Partners, Abingworth Management, Oxford Bioscience Partners and SV Life Sciences.
16 January 2013•2 mins read
PEI INFRASTRUCTURE INVESTOR
Register to unlock this content
Daily global infrastructure news and market intelligence- Expertly curated insights that keep you ahead of the market
- Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
- Access to proprietary research and reports
- Selected investor strategy and competitor performance data